person

Paolo Brambilla, Professor

as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Principal Investigator, Study Chair, Author, Investigator+Author
KOL signal score 11
4 publications · 0 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
S. C. Psichiatria - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Roles
Principal Investigator, Study Chair, Author, Investigator+Author
KOL signal
11
Publications
4 (0 high-value)
Trial investigator
yes

Publishes on

2 drugs
Cariprazine (Vraylar)Lumateperone (Caplyta)

Trials led

2
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)
NCT05351736Phase 4Unknown
The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia
NCT05322031Phase 4Completed

Publications & congress

3
Gut microbiome variability and brain alterations in schizophrenia: A scoping review of structural and functional MRI studies.
Neuroscience and biobehavioral reviews · 2026
Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force.
Bipolar disorders · 2025
Combining clozapine with cariprazine: Two case reports highlighting potential drug-drug interaction.
Schizophrenia research · 2024

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
Cariprazine (Vraylar)
drug
Lumateperone (Caplyta)
drug
PRINCIPAL_INVESTIGATOR
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)
trial
STUDY_CHAIR
The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia
trial